Decision-making around antithrombotics for stroke prevention in atrial fibrillation: the health professionals’ views

被引:0
作者
Yishen Wang
Beata Bajorek
机构
[1] The University of Technology Sydney,Graduate School of Health
[2] Royal North Shore Hospital,Pharmacy
来源
International Journal of Clinical Pharmacy | 2016年 / 38卷
关键词
Atrial fibrillation; Australia; Decision making; DOACs; Health professionals; Novel oral anticoagulant; Stroke prevention; Warfarin;
D O I
暂无
中图分类号
学科分类号
摘要
Background For stroke prevention in patients with atrial fibrillation (AF), the decision-making around antithrombotic therapy has been complicated by older age, multiple comorbidities, polypharmacy and the different pharmacological properties of warfarin and the nonvitamin K antagonist oral anticoagulants (NOACs). The complexity of decision-making has been associated with a reluctance by health professionals to use antithrombotic therapy, leading to poor clinical outcomes. In order to improve stroke prevention in patients with AF, the contemporary perspectives of health professionals on the decision-making around antithrombotic therapy needs exploration. Objective To elicit emerging themes describing health professionals’ perspectives on the decision-making around antithrombotic therapy for stroke prevention in patients with AF. Setting Sydney metropolitan area of New South Wales, Australia. Method A qualitative study based on face-to-face interviews was conducted from August to October 2014. Seven pharmacists, seven specialists, six general practitioners and six nurses practising in the Sydney metropolitan area and managing antithrombotic therapy for AF were interviewed until theme saturation was achieved in each subgroup. Interview transcripts were analysed using manual inductive coding. Main outcome measure Emerging themes describing health professionals’ perspectives on the decision-making around antithrombotic therapy for stroke prevention in patients with AF. Results Three overarching themes emerged. (1) Comprehensive assessment is necessary for decision-making but is not always implemented. Health professionals mostly focused on stroke risk assessment, not on the bleeding risk and medication safety issues. (2) Health professionals from different disciplines have different preferences for antithrombotic therapies. Although the majority of health professionals considered warfarin as the first-line therapy, NOACs were preferred by neurologists and haematologists. (3) Health professionals focused on different aspects of the decision making process: GPs and specialists were concerned about the appropriate prescription of antithrombotics, while pharmacists and nurses focused on daily medication management by patients. Conclusion The decision-making process appears to be partially preference based rather than systematic, and health professionals from various disciplines focus on different parts of the decision-making process.
引用
收藏
页码:985 / 995
页数:10
相关论文
共 50 条
[31]   Shared Decision Making in Atrial Fibrillation Where We Are and Where We Should Be Going [J].
Seaburg, Luke ;
Hess, Erik P. ;
Coylewright, Megan ;
Ting, Henry H. ;
McLeod, Christopher J. ;
Montori, Victor M. .
CIRCULATION, 2014, 129 (06) :704-710
[32]   Oral Anticoagulation in Atrial Fibrillation: Development and Evaluation of a Mobile Health Application to Support Shared Decision-Making [J].
Stephan, Laura Siga ;
Almeida, Eduardo Dytz ;
Guimaraes, Raphael Boesche ;
Ley, Antonio Gaudie ;
Mathias, Rodrigo Goncalves ;
Assis, Maria Valeria ;
Luz Leiria, Tiago Luiz .
ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2018, 110 (01) :7-14
[33]   Shared decision making for stroke prevention in atrial fibrillation: study protocol for a randomized controlled trial [J].
Marleen Kunneman ;
Megan E. Branda ;
Peter A. Noseworthy ;
Mark Linzer ;
Bruce Burnett ;
Sara Dick ;
Gabriela Spencer-Bonilla ;
Cara A. Fernandez ;
Haeshik Gorr ;
Mike Wambua ;
Shelly Keune ;
Claudia Zeballos-Palacios ;
Ian Hargraves ;
Nilay D. Shah ;
Victor M. Montori .
Trials, 18
[34]   Patients' views on stroke prevention for atrial fibrillation after an intracerebral haemorrhage: a qualitative study [J].
Ivany, Elena ;
Lotto, Robyn R. ;
Lip, Gregory Y. H. ;
Lane, Deirdre A. ;
PRESTIGE AF Consortium .
EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2025, 24 (03) :413-419
[35]   Dabigatran for stroke prevention in atrial fibrillation [J].
Hohnloser, S. H. ;
Diener, H. -C. .
HAMOSTASEOLOGIE, 2012, 32 (03) :216-220
[36]   Stroke prevention in atrial fibrillation patients [J].
Marinigh, Ricarda ;
Lip, Gregory Y. H. ;
Lane, Deirdre A. .
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (14) :2331-2350
[37]   Who Gets Stroke Prevention? Stroke Prevention in Atrial Fibrillation Patients in the Inpatient Setting [J].
Gallagher, Robyn ;
Roach, Kellie ;
Sadler, Leonie ;
Belshaw, Julie ;
Kirkness, Ann ;
Zhang, Ling ;
Proctor, Ross ;
Neubeck, Lis .
HEART LUNG AND CIRCULATION, 2015, 24 (05) :488-494
[38]   Stroke Prevention in Atrial Fibrillation: Where are We Now? [J].
Ahmad, Yousif ;
Lip, Gregory Y. H. .
CLINICAL MEDICINE INSIGHTS-CARDIOLOGY, 2012, 6 :65-78
[39]   Stroke Prevention in Atrial Fibrillation The Role of Oral Anticoagulation [J].
Mtwesi, Viwe ;
Amit, Guy .
MEDICAL CLINICS OF NORTH AMERICA, 2019, 103 (05) :847-+
[40]   Evolution of Stroke Prevention in Nonvalvular Atrial Fibrillation Patients [J].
Lee, Randall J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (01) :13-15